Cochrane · systematic review · CD006096
Interventions for treating lymphocytic colitis
Chande, N, Al Yatama, N, Bhanji, T, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 33.3%Low 6 · 66.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Bismuth subsalicylate versus placebo for treating lymphocytic colitis
Population: patients with active lymphocytic colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response Bismuth subsalicylate vs placebo | RR 5.25 [0.94, 1.9] | 1 study · 5 participants | Very low Downgraded: risk of bias, imprecision |
Histological response Bismuth subsalicylate vs placebo | RR 1.33 [0.27, 6.6] | 1 study · 5 participants | Very low Downgraded: risk of bias, imprecision |
Budesonide versus mesalazine for treating lymphocytic colitis
Population: patients with active lymphocytic colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response Budesonide vs mesalazine | RR 2.03 [1.25, 3.33] | 2 studies · 57 participants | Low Downgraded: risk of bias, imprecision |
Histological response Budesonide vs mesalazine | RR 2.44 [1.13, 5.28] | 2 studies · 39 participants | Low Downgraded: imprecision |
Adverse events Budesonide vs mesalazine | RR 0.67 [0.12, 3.59] | 1 study · 42 participants | Low Downgraded: imprecision |
Mesalazine versus mesalazine + cholestyramine for treating lymphocytic colitis
Population: patients with maintenance of remission in lymphocytic colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response Mesalazine vs mesalazine + cholestyramine | RR 0.99 [0.77, 1.28] | 1 study · 41 participants | Low Downgraded: risk of bias, imprecision |
Histological response Mesalazine vs mesalazine + cholestyramine | RR 0.99 [0.77, 1.28] | 1 study · 41 participants | Low Downgraded: risk of bias, imprecision |
Beclometasone dipropionate versus mesalazine for treating lymphocytic colitis
Population: Patients with active or quiescent lymphocytic colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response at 8 weeks Beclometasone dipropionate vs mesalazine | RR 0.97 [0.75, 1.24] | 1 study · 46 participants | Low Downgraded: risk of bias, imprecision |
Maintenance of clinical response at 12 weeks Beclometasone dipropionate vs mesalazine | RR 1.29 [0.4, 4.18] | 1 study · 46 participants | Very low Downgraded: risk of bias, imprecision |